Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of ($0.16), $0.06 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $35.2 million versus the consensus estimate of $30.09 million.

GUIDANCE:

Halozyme Therapeutics sees FY2018 revenue of $125-135 million, versus the consensus of $128 million.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.